Navigation Links
Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
Date:2/25/2013

olumes of a medication under the skin and may result in faster administration times versus intravenously (IV) administered MabThera.
  • MabThera Positive Trials: Announced positive results from Roche's SABRINA and SparkThera studies, which showed that a fixed dose of MabThera can be administered subcutaneously, potentially allowing patients to spend less time in infusion centers receiving their MabThera treatment. Specifically, the studies showed that subcutaneous injection resulted in non-inferior MabThera concentrations in the blood compared with standard IV infusion.
  • Fourth Quarter and Year End 2012 Financial ResultsThe net loss for the fourth quarter of 2012 was $4.4 million, or $0.04 per share, compared with a net loss for the fourth quarter of 2011 of $18.4 million, or $0.18 per share. The net loss for the year ended December 31, 2012 was $53.6 million, or $0.48 per share, compared to a net loss of $19.8 million, or $0.19 per share for the comparable period in 2011.

  • Revenues for the fourth quarter of 2012 were $21.8 million, compared to $2.4 million for the fourth quarter of 2011. Revenues in the fourth quarter of 2012 included license fees revenue from Pfizer of $9.5 million and a milestone payment from Roche of $4 million.
  • Research and development expenses for the fourth quarter of 2012 were $18.6 million, compared with $14.9 million for the fourth quarter of 2011. The increase was due primarily to an increase in manufacturing activities to support potential launches from our collaborators.
  • Selling, general and administrative expenses for the fourth quarter of 2012 were $7.0 million, compared to $5.9 million for the fourth quarter of 2011.
  • Cash and cash equivalents were $99.9 million as of December 31, 2012, which includes net proceeds of $29.7 million from a term loan with Oxford Finance and Silicon Vall
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
    2. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    3. Halozyme to Host Third Quarter Financial Results Conference Call
    4. Halozyme Reports Second Quarter 2012 Financial Results
    5. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
    6. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
    7. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
    8. Halozyme Reports First Quarter 2012 Financial Results
    9. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    10. Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
    11. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/2/2015)... 2015  BD (Becton, Dickinson and Company) (NYSE: ... company, today announced its participation in the White ... steps the company will take to help combat ... full range of expertise related to identification and ... information to electronic surveillance and prevention of health ...
    (Date:6/2/2015)... N.Y. , June 2, 2015 ... its first television and multi-media commercial advertisement, which ... campaign to promote SNORenz®, the company,s top selling ... of the company,s past success with television advertising. ... advertisement, but this, more modern version takes an ...
    (Date:6/2/2015)... e MADRID , June ... (abstract 10503) al meeting annuale della American Society of ... dati dello studio multicentrico di fase 3 SAR3007, resi ... , LLC (Janssen), hanno evidenziato un significativo miglioramento della ... trabectedina (YONDELIS ® ) rispetto al trattamento con dacarbazina ...
    Breaking Medicine Technology:BD Participates in White House Forum on Antibiotic Stewardship 2BD Participates in White House Forum on Antibiotic Stewardship 3Northstar releases its direct response multi-media ad designed to be used in national television advertising campaigns 2PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 2PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 3PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 4PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 5PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 6
    ... Item Q3 2009 ... $80.8 ... $78.4 16% increase, Naglazyme ... 26% increase, Aldurazyme BioMarin, Net Product Revenue $14.6 ...
    ... WAYNE, Pa., Oct. 28 Qualsec (OTC Bulletin Board: QLSZ), ... Seelig, MD has been elected as a member of the ... 25 years of clinical experience followed by 6 years of ... the first and only FDA cleared RFID medical information device ...
    Cached Medicine Technology:BioMarin Announces Third Quarter 2009 Financial Results 2BioMarin Announces Third Quarter 2009 Financial Results 3BioMarin Announces Third Quarter 2009 Financial Results 4BioMarin Announces Third Quarter 2009 Financial Results 5BioMarin Announces Third Quarter 2009 Financial Results 6BioMarin Announces Third Quarter 2009 Financial Results 7BioMarin Announces Third Quarter 2009 Financial Results 8BioMarin Announces Third Quarter 2009 Financial Results 9BioMarin Announces Third Quarter 2009 Financial Results 10BioMarin Announces Third Quarter 2009 Financial Results 11BioMarin Announces Third Quarter 2009 Financial Results 12BioMarin Announces Third Quarter 2009 Financial Results 13BioMarin Announces Third Quarter 2009 Financial Results 14BioMarin Announces Third Quarter 2009 Financial Results 15BioMarin Announces Third Quarter 2009 Financial Results 16BioMarin Announces Third Quarter 2009 Financial Results 17BioMarin Announces Third Quarter 2009 Financial Results 18VitaminSpice Appoints Dr. Richard F. Seelig as Director 2
    (Date:6/2/2015)... 02, 2015 National Autism Resource has ... web design and development agency, to launch its new ... Autism Resources’ new website is designed to ... ages diagnosed with autism. The site will expand its ... array of resources, from easy to understand information and ...
    (Date:6/2/2015)... (PRWEB) June 02, 2015 With the ... in most parts of the United States, people will ... rooms. Despite the obvious benefits of air conditioning, a ... including dry eye, dehydration and allergic reactions. Fresh water ... Power of Water® radio show, will discuss the potential ...
    (Date:6/2/2015)... (PRWEB) June 02, 2015 PhishLine, ... Headquarters to 20800 Swenson Drive, Suite 125 in ... space provides a new base of operations for ... will accommodate future growth. , Mark Chapman, Founder ... in the industry as enterprise customers adopt our ...
    (Date:6/2/2015)... Residents of Monarch Landing in Naperville are going ... class, do yoga, play volleyball, or participate in whatever ... Alzheimer’s Association’s Walk to End Alzheimer’s on September 20 ... a challenge to exercise for 60 days, sponsored by ... While the walk will raise awareness of Alzheimer’s disease ...
    (Date:6/2/2015)... June 02, 2015 TranSlice: Reveal from Pixel ... style. TranSlice: Reveal allows Final Cut Pro X users to ... to reveal their next screen. , TranSlice Reveal brings back ... Final Cut Pro X users can now transition from ... , With every panel orientation and direction covered, no transition ...
    Breaking Medicine News(10 mins):Health News:National Autism Resources Launches New Website, Delivering More Products and Services 2Health News:National Autism Resources Launches New Website, Delivering More Products and Services 3Health News:Air conditioning may contribute to dry eye, dehydration and allergies warns fresh water advocate Sharon Kleyne 2Health News:Air conditioning may contribute to dry eye, dehydration and allergies warns fresh water advocate Sharon Kleyne 3Health News:PhishLine, LLC Announces New Corporate Headquarters 2Health News:Monarch Landing Takes 60-Day Exercise Challenge to Combat Alzheimer’s 2Health News:Monarch Landing Takes 60-Day Exercise Challenge to Combat Alzheimer’s 3Health News:Announcing the release of TranSlice Reveal from Pixel Film Studios - Professional Split Screen Transitions for FCPX. 2
    ... , , SAN DIEGO, ... new exclusive agreement with Endotech SPA for distribution of its VerifyNow(R) ... growing number of distribution partners, Accumetrics now has local representation in ... , , The VerifyNow System helps physicians ...
    ... MINNEAPOLIS, Sept. 15 One in eight women will be ... all women who will be personally impacted by the disease*. Since ... celebrity breast cancer surgeon Dr. Kristi Funk are joining forces this ... of reducing breast cancer risk, early detection and meaningful ways to ...
    ... , , WHITEHALL, Pa., Sept. 15 ... has teamed up with UNFI and Select Nutrition, the nation,s ... distribute the first all-natural protein shot, Proasis((R)). , , ... , , Proasis is the market,s first ...
    ... , , , , ... Webster, is "a mythological or legendary figure often of divine descent ... children,s book author, "A hero is any person from any background ... need to know their power to be heroic." To inspire young ...
    ... , SUNNYVALE, Calif., Sept. 15 ... the field of radiosurgery, announced today that Accuray,s Board of Directors ... members of the company,s Board of Directors. , , ... areas of corporate finance, accounting and strategy. Lavigne was Chief Financial ...
    ... die of cancer but more apt to have certain malignancies, ... United States are less likely to die from cancer than ... to infections, including stomach, liver and cervix malignancies, a new ... from cancer seems to be good news, but one explanation ...
    Cached Medicine News:Health News:Accumetrics, Inc. Announces Endotech SPA as Exclusive Distributor for the VerifyNow System in Italy 2Health News:Video: Yoplait(R) and Celebrity Breast Cancer Surgeon Dr. Kristi Funk Emphasize Importance of Early Detection and Risk Reduction 2Health News:Video: Yoplait(R) and Celebrity Breast Cancer Surgeon Dr. Kristi Funk Emphasize Importance of Early Detection and Risk Reduction 3Health News:Protica Teams With UNFI/Select Nutrition to distribute All-Natural Protein Shot, Proasis 2Health News:Children's Author Tells America's Youth To 'Dream Big' By Inspiring The Hero In Every Child 2Health News:Children's Author Tells America's Youth To 'Dream Big' By Inspiring The Hero In Every Child 3Health News:Accuray Announces Additions to Board of Directors 2Health News:Accuray Announces Additions to Board of Directors 3Health News:For Hispanics, a Unique Cancer Profile Emerges 2Health News:For Hispanics, a Unique Cancer Profile Emerges 3
    The Active Ankle Trainer model provides medial/lateral support and optimum ankle mobility for chronic and prophylactic use....
    ... Bledsoe PTB Boot is designed as ... casting for the mid-tibia or fibula ... tendon bearing support. The Bledsoe EZ ... range of motion from 20 degrees ...
    ... The Bledsoe Hi-Top Boot is designed ... casting for the mid-tibia or fibula to ... third degree ankle sprains. The Bledsoe EZ ... of motion from 20 degrees of dorsi-flexion ...
    ... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
    Medicine Products: